XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...

First human trials at Rutgers Health and other institutions demonstrate better infection resistance and limb preservation ...

XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series ...

As 2024 came to a close, Ascension Saint Thomas leadership reflected on strides in healthcare innovation, community care and ...

Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve ...